← Back to Search

nNO Testing for Primary Ciliary Dyskinesia

N/A

Recruiting

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age greater than 2 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is looking at whether the current tests for Primary Ciliary Dyskinesia are effective.

Who is the study for?

This trial is for individuals suspected of having Primary Ciliary Dyskinesia (PCD) and are referred to a center for diagnosis. Participants must be able to perform the required study procedures and be older than 2 years. Those under 2 or unable to give informed consent cannot join.Check my eligibility

What is being tested?

The study is evaluating the effectiveness of current diagnostic tests for PCD, focusing on nasal nitric oxide (nNO) testing, which measures the amount of nitric oxide in breath as an indicator of ciliary function.See study design

What are the potential side effects?

Since this trial involves diagnostic testing rather than medication or invasive treatments, significant side effects are not expected. However, discomfort during nNO testing may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am older than 2 years.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of genetic tests performed

frequency of nNO tests performed

Trial Design

1Treatment groups

Experimental Treatment

Group I: Nasal Nitric Oxide testing and collection of clinical dataExperimental Treatment1 Intervention

Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

857 Previous Clinical Trials

671,993 Total Patients Enrolled

Media Library

Nasal Nitric Oxide testing and collection of clinical data Clinical Trial Eligibility Overview. Trial Name: NCT03704207 — N/A

Primary Ciliary Dyskinesia Research Study Groups: Nasal Nitric Oxide testing and collection of clinical data

Primary Ciliary Dyskinesia Clinical Trial 2023: Nasal Nitric Oxide testing and collection of clinical data Highlights & Side Effects. Trial Name: NCT03704207 — N/A

Nasal Nitric Oxide testing and collection of clinical data 2023 Treatment Timeline for Medical Study. Trial Name: NCT03704207 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities to participate in this clinical experiment?

"From clinicaltrials.gov, it can be ascertained that this research is currently seeking participants. The study was initially posted on June 1st 2017 and the most recently available update was made on November 16th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Utility of PCD Diagnostics to Improve Clinical Care

Michael O'Connor 2017. "Utility of PCD Diagnostics to Improve Clinical Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03704207.